2023
Feasibility and Toxicity of Full-Body Volumetric Modulated Arc Therapy Technique for High-Dose Total Body Irradiation
Keit E, Liveringhouse C, Figura N, Weygand J, Sandoval M, Garcia G, Peters J, Nieder M, Faramand R, Khimani F, Kim S, Robinson T, Johnstone P, Penagaricano J, Latifi K. Feasibility and Toxicity of Full-Body Volumetric Modulated Arc Therapy Technique for High-Dose Total Body Irradiation. Technology In Cancer Research & Treatment 2023, 22: 15330338231180779. PMID: 37287260, PMCID: PMC10272663, DOI: 10.1177/15330338231180779.Peer-Reviewed Original ResearchConceptsHigh-dose total body irradiationTotal body irradiationHelical tomotherapyBody irradiationDosimetric outcomesLower lung dosesMucosal sparing techniquesArc therapy (VMAT) techniqueMucosal sparingHead-first positionMyeloablative conditioningDaily fractionsLung dosesAcute leukemiaPrescription doseHT plansDose goalsFFS plansOAR sparingPatientsLow dosesArc therapyUnique protocolDosesVMAT plans
2022
Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes
Figura N, Sim A, Jain M, Chavez J, Robinson T. Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes. Expert Review Of Hematology 2022, 15: 1023-1030. PMID: 36369950, DOI: 10.1080/17474086.2022.2147919.Peer-Reviewed Original ResearchConceptsCAR T-cell therapyT-cell therapySalvage radiotherapyPatient outcomesAnti-CD19 chimeric antigen receptor (CAR) T-cell therapyChimeric antigen receptor T-cell therapyLarge B-cell lymphomaCurrent retrospective dataHigh tumor burdenClinical risk factorsAblative radiation dosesHypothesis-driven clinical trialsB-cell lymphomaMost patientsR DLBCLLocal recurrenceTumor burdenClinical evidenceRisk factorsTreatment paradigmClinical trialsTreatment outcomesRadiation therapyElevated riskPatientsPredicting Stereotactic Radiosurgery Dose Maps from Pre-Therapy MR Images using a Deep Neural Network
Pandey S, Kutuk T, Mills M, Abdalah M, Stringfield O, Latifi K, Robinson T, Moreno W, Ahmed K, Raghunand N. Predicting Stereotactic Radiosurgery Dose Maps from Pre-Therapy MR Images using a Deep Neural Network. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2022 DOI: 10.58530/2022/4966.Peer-Reviewed Original ResearchDose mapsStereotactic radiosurgeryPre-RTMR imagingRadiation treatmentAsymptomatic brain metastasesMR images of patientsImages of patientsDoses of radiation treatmentVoxel intensitiesTumor controlBrain metastasesTumor responsePre-therapyTumorHealthy brainBrainRadiosurgeryMetastasizingMetastasisPatientsBreastDose
2021
Lymphoplasmacytic lymphoma manifesting as a cervical spine mass with Parkinson-like symptoms treated with ibrutinib
Tan E, Tran N, Peguero E, Robinson T, Gaballa S. Lymphoplasmacytic lymphoma manifesting as a cervical spine mass with Parkinson-like symptoms treated with ibrutinib. Current Problems In Cancer Case Reports 2021, 3: 100046. DOI: 10.1016/j.cpccr.2020.100046.Peer-Reviewed Original ResearchParkinson-like symptomsCentral nervous system involvementNervous system involvementEfficacy of ibrutinibIgM monoclonal gammopathyRare B-cell malignancyB-cell malignanciesLymphoma involvementPatient's symptomsRare presentationLumbar punctureDiagnostic workupSystem involvementMonoclonal gammopathyLymphoplasmacytic lymphomaPatient historyLow doseBone marrowSymptomsIbrutinibLPLInvolvementBiopsyPatientsGammopathy
2020
Brain Metastases Outcomes In Patients With Melanoma, Non-Small Cell Lung Cancer, And Breast Cancer And Implications For Screening Brain MRIs
Potluri T, Fahey M, Kawahara Y, Mills M, Figura N, Washington I, Diaz R, Robinson T, Yu H, Etame A, Czerniecki B, Arrington J, Forsyth P, Soliman H, Han H, Ahmed K. Brain Metastases Outcomes In Patients With Melanoma, Non-Small Cell Lung Cancer, And Breast Cancer And Implications For Screening Brain MRIs. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e701-e702. DOI: 10.1016/j.ijrobp.2020.07.057.Peer-Reviewed Original ResearchClinical Outcomes of Breast Cancer Patients with HER2-positive Brain Metastases Treated with Stereotactic Radiation and Trastuzumab Emtansine
Mills M, Walker C, Thawani C, Naz A, Figura N, Yu M, Robinson T, Etame A, Liu J, Vogelbaum M, Forsyth P, Soliman H, Han H, Ahmed K. Clinical Outcomes of Breast Cancer Patients with HER2-positive Brain Metastases Treated with Stereotactic Radiation and Trastuzumab Emtansine. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e679-e680. DOI: 10.1016/j.ijrobp.2020.07.2026.Peer-Reviewed Original ResearchPD39-06 POOR RESPONSE TO IMMUNOTHERAPY IS ASSOCIATED WITH HIGH EXPRESSION OF A NOVEL EPIDERMAL GROWTH FACTOR RECEPTOR SPLICE VARIANT IN PATIENTS WITH RENAL CELL CARCINOMA
Hajiran* A, Kim Y, Zaman S, Madanyake T, Robinson T, Falasiri S, Spiess P, Kohli M, Boyle T, Mulé J, Teer J, Manley B. PD39-06 POOR RESPONSE TO IMMUNOTHERAPY IS ASSOCIATED WITH HIGH EXPRESSION OF A NOVEL EPIDERMAL GROWTH FACTOR RECEPTOR SPLICE VARIANT IN PATIENTS WITH RENAL CELL CARCINOMA. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000918.06.Peer-Reviewed Original Research
2019
CMET-17. RENAL CELL CARCINOMA BRAIN METASTASES TREATED WITH STEREOTACTIC RADIATION THERAPY AND NIVOLUMAB DOES NOT ALTER LESIONAL OR CLINICAL OUTCOMES
Mohammadi H, Tolpin A, Figura N, Peacock J, Oliver D, Sim A, Palm R, Ahmed K, Liu J, Tran N, Etame A, Vogelbaum M, Robinson T, Yu M. CMET-17. RENAL CELL CARCINOMA BRAIN METASTASES TREATED WITH STEREOTACTIC RADIATION THERAPY AND NIVOLUMAB DOES NOT ALTER LESIONAL OR CLINICAL OUTCOMES. Neuro-Oncology 2019, 21: vi54-vi55. PMCID: PMC6847278, DOI: 10.1093/neuonc/noz175.218.Peer-Reviewed Original ResearchStereotactic radiotherapyMedian timeRenal cell carcinoma brain metastasesDistant brain failureStage IV RCCMedian overall survivalOptimal treatment sequenceCox regression modelStereotactic radiation therapyWarrants further investigationDistant brainEligible lesionsNivolumab administrationBrain metastasesConsecutive patientsOverall survivalClinical outcomesBrain failureKaplan-MeierRetrospective databaseHemorrhagic lesionsNivolumabRadiation therapyPatient basisPatients
2018
Response to Local Treatment Modalities in Patients with Primary Cutaneous CD4+ Small/Medium Pleomorphic T-Cell Lymphoma
Yuan Z, Grass G, Robinson T, Kim S. Response to Local Treatment Modalities in Patients with Primary Cutaneous CD4+ Small/Medium Pleomorphic T-Cell Lymphoma. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e379-e380. DOI: 10.1016/j.ijrobp.2018.07.1130.Peer-Reviewed Original Research